CA2873890C - Methods and compositions for treating amyloid deposits - Google Patents

Methods and compositions for treating amyloid deposits Download PDF

Info

Publication number
CA2873890C
CA2873890C CA2873890A CA2873890A CA2873890C CA 2873890 C CA2873890 C CA 2873890C CA 2873890 A CA2873890 A CA 2873890A CA 2873890 A CA2873890 A CA 2873890A CA 2873890 C CA2873890 C CA 2873890C
Authority
CA
Canada
Prior art keywords
apoe
protective
mammal
protein
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2873890A
Other languages
English (en)
French (fr)
Other versions
CA2873890A1 (en
Inventor
Beverly L. Davidson
Bradley T. Hyman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation UIRF
General Hospital Corp
Original Assignee
University of Iowa Research Foundation UIRF
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Iowa Research Foundation UIRF, General Hospital Corp filed Critical University of Iowa Research Foundation UIRF
Publication of CA2873890A1 publication Critical patent/CA2873890A1/en
Application granted granted Critical
Publication of CA2873890C publication Critical patent/CA2873890C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2873890A 2012-05-18 2013-03-14 Methods and compositions for treating amyloid deposits Active CA2873890C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648801P 2012-05-18 2012-05-18
US61/648,801 2012-05-18
PCT/US2013/031725 WO2013172964A1 (en) 2012-05-18 2013-03-14 Methods and compositions for treating amyloid deposits

Publications (2)

Publication Number Publication Date
CA2873890A1 CA2873890A1 (en) 2013-11-21
CA2873890C true CA2873890C (en) 2022-12-06

Family

ID=49584137

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2873890A Active CA2873890C (en) 2012-05-18 2013-03-14 Methods and compositions for treating amyloid deposits

Country Status (12)

Country Link
US (1) US20150183850A1 (OSRAM)
EP (1) EP2850195B1 (OSRAM)
JP (2) JP6469000B2 (OSRAM)
CN (2) CN104540952A (OSRAM)
AU (1) AU2013263346B2 (OSRAM)
BR (1) BR112014028666B1 (OSRAM)
CA (1) CA2873890C (OSRAM)
ES (1) ES2786078T3 (OSRAM)
HK (1) HK1207109A1 (OSRAM)
IN (1) IN2014KN02672A (OSRAM)
RU (1) RU2673484C2 (OSRAM)
WO (1) WO2013172964A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112375760A (zh) 2014-11-14 2021-02-19 沃雅戈治疗公司 调节性多核苷酸
WO2016196507A1 (en) 2015-05-29 2016-12-08 University Of Iowa Research Foundation Methods of delivery of transgenes for treating brain diseases
EP3307391A1 (en) * 2015-06-12 2018-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of alzheimer's disease
WO2017179646A1 (ja) * 2016-04-14 2017-10-19 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイド（ａｓｐｄ）様構造体及び医薬組成物
IL302748B1 (en) 2016-05-18 2025-09-01 Voyager Therapeutics Inc Modulatory polynucleotides
MX2019001421A (es) * 2016-08-03 2019-09-04 Univ South Florida Composiciones de reelina para el tratamiento de trastornos neurologicos.
MX2019002518A (es) * 2016-09-02 2019-07-18 Spark Therapeutics Inc Metodos y vectores para el tratamiento de trastornos del snc.
EP3309550A1 (en) * 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
KR20220010062A (ko) 2017-10-03 2022-01-25 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
KR102709597B1 (ko) 2017-10-03 2024-09-26 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
JP7616995B2 (ja) * 2018-11-28 2025-01-17 プリベイル セラピューティクス，インコーポレーテッド 神経変性疾患のための遺伝子治療
CA3157864A1 (en) * 2019-10-16 2021-04-22 Cornell University Gene therapy for alzheimer's disease
IL296494A (en) * 2020-03-31 2022-11-01 Nuo Beta Pharmarceutical Tech Shanghai Co Ltd Deuterated oxophenylarsine compound and use thereof
CA3203006A1 (en) * 2020-11-25 2022-06-02 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative disease
WO2023108507A1 (en) * 2021-12-15 2023-06-22 National Institute Of Biological Sciences, Beijing Recombinant aav vectors and use thereof
CN116063405B (zh) * 2022-09-27 2025-08-29 广州译码基因科技有限公司 可提高AAV病毒包装能力的衣壳蛋白突变体MutC及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US6436996B1 (en) * 1997-09-30 2002-08-20 Duke University Modulation of nitric oxide production
US6468524B1 (en) 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US6855314B1 (en) 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
EP1828390B1 (en) * 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
MX2007013734A (es) * 2005-05-02 2008-03-14 Genzyme Corp Terapia genica para trastornos de la medula espinal.
AU2007294858B2 (en) * 2006-09-14 2011-05-12 Medgenics Medical Israel, Ltd Long lasting drug formulations
PL2154969T3 (pl) * 2007-05-16 2016-04-29 Brigham & Womens Hospital Inc Leczenie synukleinopatii
JP2013533847A (ja) * 2010-04-23 2013-08-29 ユニバーシティ オブ マサチューセッツ コレステロール関連障害のａａｖベースの治療

Also Published As

Publication number Publication date
EP2850195B1 (en) 2020-01-22
HK1207109A1 (en) 2016-01-22
AU2013263346A1 (en) 2014-12-04
EP2850195A4 (en) 2015-12-09
IN2014KN02672A (OSRAM) 2015-05-08
BR112014028666A2 (pt) 2017-06-27
EP2850195A1 (en) 2015-03-25
RU2673484C2 (ru) 2018-11-27
JP2019031564A (ja) 2019-02-28
BR112014028666B1 (pt) 2021-12-07
ES2786078T3 (es) 2020-10-08
WO2013172964A1 (en) 2013-11-21
CN104540952A (zh) 2015-04-22
CA2873890A1 (en) 2013-11-21
RU2014151218A (ru) 2016-07-10
JP6469000B2 (ja) 2019-02-13
AU2013263346B2 (en) 2018-08-23
CN112574964A (zh) 2021-03-30
JP2015520161A (ja) 2015-07-16
US20150183850A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
CA2873890C (en) Methods and compositions for treating amyloid deposits
AU2017318717B2 (en) Methods and vectors for treating CNS disorders
EP3071240B1 (en) Method for monitoring efficacy of treatment of alzheimer's disease with an apoe isoform
WO2022155435A1 (en) Treating diseases and improving nucleic acid delivery
HK1229258B (en) Method for monitoring efficacy of treatment of alzheimer's disease with an apoe isoform
HK1229258A1 (en) Method for monitoring efficacy of treatment of alzheimer's disease with an apoe isoform
EP4410988A1 (en) An aav2-vector variant for targeted transfer of genes
US20240115736A1 (en) Methods and materials for treating tdp-43 proteinopathies
BR112016011258B1 (pt) Métodos e composiçôes para o tratamento de depósitos de amiloide
KR20250112089A (ko) 퇴행성 뇌 질환의 예방 또는 치료를 위한 뇌혈관 특이적 유전자 치료용 조성물

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180308

EEER Examination request

Effective date: 20180308

EEER Examination request

Effective date: 20180308